Delphi Ventures
Deepa Pakianathan, Ph.D. joined PTC's board of directors in 2009.  She is a general partner at Delphi Ventures and leads the firm's biotechnology investment activities. Prior to joining Delphi, Deepa was a Vice President in the healthcare group at JP Morgan. From 1997 to 1998, Deepa was a biotechnology research analyst at Genesis Merchant Group. She worked as a postdoctoral scientist in the Immunology Department at Genentech Corporation from 1993 to 1997, where she evaluated chemokines and chemokine receptors as targets for therapeutic intervention. Deepa received a Ph.D. and an M.S. from Wake Forest University, and an M.Sc. and a B.Sc. from the University of Bombay.  She serves on the boards of Alder BioPharmaceuticals, Inc., Alexza Pharmaceuticals, Inc., NeurAxon, Inc., OncoMed Pharmaceuticals, Inc., Phenomix Corporation and Relypsa, Inc. She also serves on the Board of Trustees of the San Francisco Conservatory of Music.